You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameHydromorphone
Accession NumberDB00327  (APRD01021)
TypeSmall Molecule
GroupsApproved, Illicit
Description

An opioid analgesic derived from morphine and used mainly as an analgesic. It has a shorter duration of action and is more potent than morphine. [PubChem]

Structure
Thumb
Synonyms
(-)-(5R)-4,5-Epoxy-3-hydroxy-9alpha-methylmorphinan-6-one
4,5-Epoxy-3-hydroxy-17-methylmorphinan-6-one
4,5alpha-Epoxy-3-hydroxy-17-methyl-6-morphinanone
6-Deoxy-7,8-dihydro-6-oxomorphine
7,8-Dihydromorphinone
Dihydromorfinon
Dihydromorphinone
Dimorphone
Hidromorfona
Hydromorfona
Hydromorphone
Hydromorphonum
Idromorfone
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dilaudidtablet4 mgoralPurdue Pharma1984-12-31Not applicableCanada
Dilaudidtablet8 mgoralPurdue Pharma1989-12-31Not applicableCanada
Dilaudidinjection, solution1 mg/mLintramuscular; intravenous; subcutaneousPurdue Pharma LP1926-01-01Not applicableUs
Dilaudidinjection, solution4 mg/mLintramuscular; intravenous; subcutaneousPurdue Pharma LP1926-01-01Not applicableUs
Dilaudidtablet8 mg/1oralPurdue Pharma LP1956-01-01Not applicableUs
Dilaudidtablet2 mgoralPurdue Pharma1984-12-31Not applicableCanada
Dilaudidtablet4 mg/1oralPurdue Pharma LP1956-01-01Not applicableUs
Dilaudidliquid2 mgintramuscular; intravenous; subcutaneousPurdue Pharma1984-12-31Not applicableCanada
Dilaudidtablet2 mg/1oralPurdue Pharma LP1956-01-01Not applicableUs
Dilaudidtablet4 mg/1oralCardinal Health1926-01-01Not applicableUs
Dilaudidliquid5 mg/5mLoralPurdue Pharma LP1956-01-01Not applicableUs
Dilaudidtablet2 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-12-01Not applicableUs
Dilaudidliquid1 mgoralPurdue Pharma1989-12-31Not applicableCanada
Dilaudidpowder for solution250 mgintramuscular; intravenous; subcutaneousPurdue Pharma1994-12-312013-06-07Canada
Dilaudidtablet4 mg/1oralLake Erie Medical DBA Quality Care Products LLC1956-01-01Not applicableUs
Dilaudidinjection, solution2 mg/mLintramuscular; intravenous; subcutaneousPurdue Pharma LP1926-01-01Not applicableUs
Dilaudidtablet1 mgoralPurdue Pharma1986-12-31Not applicableCanada
Dilaudidsuppository3 mgrectalPurdue Pharma1984-12-312010-08-05Canada
Dilaudid Hpliquid10 mgintramuscular; intravenous; subcutaneousPurdue Pharma1984-12-31Not applicableCanada
Dilaudid Hpinjection, powder, lyophilized, for solution10 mg/mLintramuscular; intravenous; subcutaneousPurdue Pharma LP1984-01-11Not applicableUs
Dilaudid Hpinjection, solution10 mg/mLintramuscular; intravenous; subcutaneousPurdue Pharma LP1984-01-11Not applicableUs
Dilaudid-HP-plussolution20 mgintramuscular; intravenous; subcutaneousPurdue Pharma1995-12-312012-08-02Canada
Dilaudid-XPliquid50 mgintramuscular; intravenous; subcutaneousPurdue Pharma1995-12-312012-08-02Canada
Exalgotablet, extended release8 mg/1oralMallinckrodt, Inc2011-03-14Not applicableUs
Exalgotablet, extended release16 mg/1oralMallinckrodt, Inc2011-03-14Not applicableUs
Exalgotablet, extended release8 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-03-14Not applicableUs
Exalgotablet, extended release8 mg/1oralSTAT Rx USA LLC2011-03-14Not applicableUs
Exalgotablet, extended release16 mg/1oralPhysicians Total Care, Inc.2012-12-31Not applicableUs
Exalgotablet, extended release16 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-03-14Not applicableUs
Exalgotablet, extended release8 mg/1oralPhysicians Total Care, Inc.2012-12-31Not applicableUs
Exalgotablet, extended release12 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-03-14Not applicableUs
Exalgotablet, extended release12 mg/1oralMallinckrodt, Inc2011-03-14Not applicableUs
Exalgotablet, extended release32 mg/1oralMallinckrodt, Inc2012-08-24Not applicableUs
Hydromorph Contincapsule (sustained-release)9.0 mgoralPurdue Pharma2011-04-14Not applicableCanada
Hydromorph Contincapsule (sustained-release)4.5 mgoralPurdue Pharma2011-04-14Not applicableCanada
Hydromorph Contin-controlled Release Cap - 12mgcapsule (sustained-release)12 mgoralPurdue Pharma1996-12-31Not applicableCanada
Hydromorph Contin-controlled Release Cap - 18mgcapsule (sustained-release)18 mgoralPurdue Pharma2001-07-03Not applicableCanada
Hydromorph Contin-controlled Release Cap - 24mgcapsule (sustained-release)24 mgoralPurdue Pharma1996-12-31Not applicableCanada
Hydromorph Contin-controlled Release Cap - 30mgcapsule (sustained-release)30 mgoralPurdue Pharma1998-02-16Not applicableCanada
Hydromorph Contin-controlled Release Cap - 3mgcapsule (sustained-release)3 mgoralPurdue Pharma1995-12-31Not applicableCanada
Hydromorph Contin-controlled Release Cap - 6mgcapsule (sustained-release)6 mgoralPurdue Pharma1995-12-31Not applicableCanada
Hydromorph.ir - 2mgtablet2 mgoralPurdue Pharma2002-12-192012-08-02Canada
Hydromorph.ir - 4mgtablet4 mgoralPurdue Pharma2002-12-192012-08-02Canada
Hydromorph.ir - 8mgtablet8 mgoralPurdue Pharma2002-12-192012-08-02Canada
Hydromorphonetablet4 mgoralSorres Pharma Inc2004-04-062014-06-20Canada
Hydromorphonetablet8 mgoralSorres Pharma Inc2004-04-062014-06-20Canada
Hydromorphonetablet1 mgoralSorres Pharma Inc2004-04-062014-06-20Canada
Hydromorphonetablet2 mgoralSorres Pharma Inc2004-04-062014-06-20Canada
Hydromorphone HCl Tab 2mg USPtablet2 mgoralRoxane Labs, Division Of Boehringer Ingelheim1992-12-312001-07-30Canada
Hydromorphone HCl Tab 4mg USPtablet4 mgoralRoxane Labs, Division Of Boehringer Ingelheim1992-12-312001-07-30Canada
Hydromorphone Hp 10solution10 mgintramuscular; intravenous; subcutaneousSandoz Canada Incorporated1995-12-31Not applicableCanada
Hydromorphone Hp 20solution20 mgintramuscular; intravenous; subcutaneousSandoz Canada Incorporated1995-12-31Not applicableCanada
Hydromorphone Hp 50solution50 mgintramuscular; intravenous; subcutaneousSandoz Canada Incorporated1995-12-31Not applicableCanada
Hydromorphone Hp Forte Injectionsolution100 mgintramuscular; intravenous; subcutaneousSandoz Canada Incorporated2001-12-10Not applicableCanada
Hydromorphone Hydrochlorideinjection, solution2 mg/mLintramuscular; intravenous; subcutaneousHospira, Inc.2011-12-01Not applicableUs
Hydromorphone Hydrochlorideinjection, solution4 mg/mLintramuscular; intravenous; subcutaneousHospira, Inc.2011-12-01Not applicableUs
Hydromorphone Hydrochloridetablet8 mg/1oralSTAT Rx USA LLC2009-11-23Not applicableUs
Hydromorphone Hydrochlorideinjection, solution1 mg/mLintramuscular; intravenous; subcutaneousHospira, Inc.2011-12-01Not applicableUs
Hydromorphone Hydrochlorideinjection, solution2 mg/mLintramuscular; intravenous; subcutaneousHospira, Inc.2011-12-01Not applicableUs
Hydromorphone Hydrochloridesolution5 mg/5mLoralRhodes Pharmaceuticals L.P.2012-07-20Not applicableUs
Hydromorphone Hydrochloridetablet2 mg/1oralAvera Mc Kennan Hospital2015-05-28Not applicableUs
Hydromorphone Hydrochlorideinjection, solution2 mg/mLintramuscular; intravenous; subcutaneousHospira, Inc.2011-12-01Not applicableUs
Hydromorphone Hydrochloridetablet8 mg/1oralRhodes Pharmaceuticals L.P.2009-11-23Not applicableUs
Hydromorphone Hydrochloridetablet2 mg/1oralbryant ranch prepack2009-11-23Not applicableUs
Hydromorphone Hydrochloridetablet4 mg/1oralRhodes Pharmaceuticals L.P.2009-11-23Not applicableUs
Hydromorphone Hydrochlorideinjection, solution1 mg/mLintramuscular; intravenous; subcutaneousHospira, Inc.2011-12-01Not applicableUs
Hydromorphone Hydrochloridetablet4 mg/1oralbryant ranch prepack2009-11-23Not applicableUs
Hydromorphone Hydrochloridetablet2 mg/1oralRhodes Pharmaceuticals L.P.2009-11-23Not applicableUs
Hydromorphone Hydrochlorideinjection, solution4 mg/mLintramuscular; intravenous; subcutaneousHospira, Inc.2011-12-01Not applicableUs
Hydromorphone Hydrochloride Extended-releasetablet, extended release8 mg/1oralMallinckrodt, Inc.2014-06-12Not applicableUs
Hydromorphone Hydrochloride Extended-releasetablet, extended release32 mg/1oralMallinckrodt, Inc.2014-06-12Not applicableUs
Hydromorphone Hydrochloride Extended-releasetablet, extended release16 mg/1oralMallinckrodt, Inc.2014-06-12Not applicableUs
Hydromorphone Hydrochloride Extended-releasetablet, extended release12 mg/1oralMallinckrodt, Inc.2014-06-12Not applicableUs
Hydromorphone Hydrochloride Injection USPsolution2 mgintramuscular; intravenous; subcutaneousSandoz Canada Incorporated1995-12-31Not applicableCanada
Hydromorphone Hydrochloride Injection USP Hp 10solution10 mgintramuscular; intravenous; subcutaneousHospira Healthcare Corporation2014-06-11Not applicableCanada
Hydromorphone Hydrochloride Sup 3mgsuppository3 mgrectalSandoz Canada Incorporated1992-12-312012-01-23Canada
Jurnistatablet (extended-release)4 mgoralJanssen Inc2010-03-04Not applicableCanada
Jurnistatablet (extended-release)32 mgoralJanssen Inc2010-03-04Not applicableCanada
Jurnistatablet (extended-release)16 mgoralJanssen Inc2010-03-04Not applicableCanada
Jurnistatablet (extended-release)8 mgoralJanssen Inc2010-03-04Not applicableCanada
Palladone XL - 12mgcapsule (controlled-delivery)12 mgoralPurdue Pharma2002-12-192005-08-05Canada
Palladone XL - 16mgcapsule (controlled-delivery)16 mgoralPurdue Pharma2002-12-192005-08-05Canada
Palladone XL - 24mgcapsule (controlled-delivery)24 mgoralPurdue Pharma2002-12-192005-08-05Canada
PHL-hydromorphonesuppository3 mgrectalPharmel IncNot applicableNot applicableCanada
PHL-hydromorphone -syr 1mg/mlsyrup1 mgoralPharmel IncNot applicableNot applicableCanada
PMS Hydromorphone Sirop 1mg/mlsyrup1 mgoralPharmascience Inc1991-12-31Not applicableCanada
PMS Hydromorphone Suppositoire 3mgsuppository3 mgrectalPharmascience Inc1991-12-31Not applicableCanada
PMS-hydromorphone Tab 1mgtablet1 mgoralPharmascience Inc1991-12-31Not applicableCanada
PMS-hydromorphone Tab 2mgtablet2 mgoralPharmascience Inc1991-12-31Not applicableCanada
PMS-hydromorphone Tab 4mgtablet4 mgoralPharmascience Inc1991-12-31Not applicableCanada
PMS-hydromorphone Tab 8mgtablet8 mgoralPharmascience Inc1991-12-31Not applicableCanada
Teva-hydromorphonetablet8 mgoralTeva Canada Limited2011-11-16Not applicableCanada
Teva-hydromorphonetablet4 mgoralTeva Canada Limited2011-11-16Not applicableCanada
Teva-hydromorphonetablet2 mgoralTeva Canada Limited2011-11-16Not applicableCanada
Teva-hydromorphonetablet1 mgoralTeva Canada Limited2011-11-16Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-hydromorphonetablet2 mgoralApotex Inc2012-12-18Not applicableCanada
Apo-hydromorphonetablet8 mgoralApotex Inc2012-12-18Not applicableCanada
Apo-hydromorphonetablet1 mgoralApotex Inc2012-12-18Not applicableCanada
Apo-hydromorphonetablet4 mgoralApotex Inc2012-12-18Not applicableCanada
Hydromorphone Hydrochloridetablet4 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-29Not applicableUs
Hydromorphone Hydrochloridetablet, extended release8 mg/1oralWatson Laboratories, Inc.2014-05-21Not applicableUs
Hydromorphone Hydrochloridetablet8 mg/1oralTAGI Pharma, Inc.2012-03-09Not applicableUs
Hydromorphone Hydrochloridetablet, extended release12 mg/1oralWatson Laboratories, Inc.2014-05-21Not applicableUs
Hydromorphone Hydrochloridetablet4 mg/1oralRoxane Laboratories, Inc2009-07-29Not applicableUs
Hydromorphone Hydrochloridetablet, film coated4 mg/1oralPhysicians Total Care, Inc.2004-01-07Not applicableUs
Hydromorphone Hydrochloridetablet2 mg/1oralLake Erie Medical DBA Quality Care Products LLC2009-05-14Not applicableUs
Hydromorphone Hydrochlorideinjection, solution10 mg/mLintramuscular; intravenous; subcutaneousHospira, Inc.2008-06-17Not applicableUs
Hydromorphone Hydrochloridetablet, extended release16 mg/1oralPaddock Laboratories, LLC2015-05-22Not applicableUs
Hydromorphone Hydrochloridetablet2 mg/1oralPd Rx Pharmaceuticals, Inc.2009-12-09Not applicableUs
Hydromorphone Hydrochloridetablet8 mg/1oralMallinckrodt, Inc.2009-05-14Not applicableUs
Hydromorphone Hydrochloridetablet, film coated8 mg/1oralPhysicians Total Care, Inc.2002-02-06Not applicableUs
Hydromorphone Hydrochlorideinjection10 mg/mLparenteralAkorn, Inc.2010-05-15Not applicableUs
Hydromorphone Hydrochloridetablet, extended release12 mg/1oralPaddock Laboratories, LLC2015-05-22Not applicableUs
Hydromorphone Hydrochloridetablet2 mg/1oralSTAT Rx USA LLC2007-09-19Not applicableUs
Hydromorphone Hydrochloridetablet4 mg/1oralMallinckrodt, Inc.2009-05-14Not applicableUs
Hydromorphone Hydrochloridetablet, film coated2 mg/1oralPhysicians Total Care, Inc.2004-09-20Not applicableUs
Hydromorphone Hydrochloridetablet2 mg/1oralSTAT Rx USA LLC2009-05-14Not applicableUs
Hydromorphone Hydrochloridetablet, extended release8 mg/1oralPaddock Laboratories, LLC2015-05-22Not applicableUs
Hydromorphone Hydrochloridetablet8 mg/1oralAmerican Health Packaging2014-08-14Not applicableUs
Hydromorphone Hydrochloridetablet4 mg/1oralSTAT Rx USA LLC2007-09-19Not applicableUs
Hydromorphone Hydrochloridetablet2 mg/1oralMallinckrodt, Inc.2009-05-14Not applicableUs
Hydromorphone Hydrochloridetablet2 mg/1oralH.J. Harkins Company, Inc.2009-12-09Not applicableUs
Hydromorphone Hydrochlorideinjection, solution10 mg/mLintramuscular; intravenous; subcutaneousTeva Parenteral Medicines, Inc.2011-01-18Not applicableUs
Hydromorphone Hydrochloridetablet8 mg/1oralLannett Company, Inc.2009-12-09Not applicableUs
Hydromorphone Hydrochloridetablet4 mg/1oralAmerican Health Packaging2013-07-17Not applicableUs
Hydromorphone Hydrochloridetablet2 mg/1oralLake Erie Medical DBA Quality Care Products LLC2009-12-09Not applicableUs
Hydromorphone Hydrochloridesolution1 mg/mLoralRoxane Laboratories, Inc2012-03-01Not applicableUs
Hydromorphone Hydrochloridetablet8 mg/1oralH.J. Harkins Company, Inc.2009-12-09Not applicableUs
Hydromorphone Hydrochlorideinjection, solution10 mg/mLintramuscular; intravenous; subcutaneousTeva Parenteral Medicines, Inc.2011-01-18Not applicableUs
Hydromorphone Hydrochloridetablet2 mg/1oralAmerican Health Packaging2013-07-17Not applicableUs
Hydromorphone Hydrochloridetablet4 mg/1oralLake Erie Medical DBA Quality Care Products LLC2009-12-09Not applicableUs
Hydromorphone Hydrochloridetablet4 mg/1oralLannett Company, Inc.2009-12-09Not applicableUs
Hydromorphone Hydrochloridetablet8 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-04-26Not applicableUs
Hydromorphone Hydrochloridetablet, extended release16 mg/1oralWatson Laboratories, Inc.2014-05-21Not applicableUs
Hydromorphone Hydrochloridetablet8 mg/1oralRoxane Laboratories, Inc2009-07-29Not applicableUs
Hydromorphone Hydrochloridetablet4 mg/1oralH.J. Harkins Company, Inc.2009-12-09Not applicableUs
Hydromorphone Hydrochlorideinjection, solution10 mg/mLintramuscular; intravenous; subcutaneousTeva Parenteral Medicines, Inc.2011-01-18Not applicableUs
Hydromorphone Hydrochloridetablet8 mg/1oralbryant ranch prepack2009-07-29Not applicableUs
Hydromorphone Hydrochloridetablet8 mg/1oralLake Erie Medical DBA Quality Care Products LLC2009-12-09Not applicableUs
Hydromorphone Hydrochloridetablet2 mg/1oralLannett Company, Inc.2009-12-09Not applicableUs
Hyrdomorphone Hydrochloridetablet8 mg/1oralPrecision Dose Inc.2014-02-17Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Hydromorphone HClinjection, solution1 mg/mLintravenousCantrell Drug Company2011-06-30Not applicableUs
Hydromorphone HClinjection, solution.5 mg/mLintramuscular; intravenous; subcutaneousCantrell Drug Company2012-01-18Not applicableUs
Hydromorphone HClinjection, solution.1 mg/mLintravenousCantrell Drug Company2014-08-21Not applicableUs
Hydromorphone HClinjection, solution.2 mg/mLintravenousCantrell Drug Company2010-08-23Not applicableUs
Hydromorphone HClinjection, solution2 mg/mLintravenousCantrell Drug Company2014-08-13Not applicableUs
Hydromorphone HClinjection, solution.4 mg/mLintravenousCantrell Drug Company2014-08-13Not applicableUs
Hydromorphone HClinjection, solution10 mg/mLintravenousCantrell Drug Company2014-08-13Not applicableUs
Hydromorphone Hydrochloridesuppository3 mg/1rectalPaddock Laboratories, LLC1996-01-31Not applicableUs
Hydromorphone Hydrochlorideinjection2 mg/mLintramuscular; intravenous; subcutaneousWest Ward Pharmaceutical Corp.1972-01-01Not applicableUs
Hydromorphone Hydrochlorideinjection2 mg/mLintramuscular; intravenous; subcutaneousWest Ward Pharmaceutical Corp.1972-01-01Not applicableUs
International Brands
NameCompany
PalladoneNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Hydromorphone Hydrochloride
71-68-1
Thumb
  • InChI Key: XHILEZUETWRSHC-NRGUFEMZSA-N
  • Monoisotopic Mass: 321.113171218
  • Average Mass: 321.799
DBSALT000444
Categories
UNIIQ812464R06
CAS number466-99-9
WeightAverage: 285.3377
Monoisotopic: 285.136493479
Chemical FormulaC17H19NO3
InChI KeyInChIKey=WVLOADHCBXTIJK-YNHQPCIGSA-N
InChI
InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,16,19H,3,5-8H2,1H3/t10-,11+,16-,17-/m0/s1
IUPAC Name
(1S,5R,13R,17R)-10-hydroxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7(18),8,10-trien-14-one
SMILES
[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassMorphinans
Sub ClassNot Available
Direct ParentMorphinans
Alternative Parents
Substituents
  • Morphinan
  • Benzylisoquinoline
  • Phenanthrene
  • Isoquinolone
  • Tetralin
  • Benzofuran
  • Aralkylamine
  • Cyclohexanone
  • Alkyl aryl ether
  • Benzenoid
  • Piperidine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Ketone
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the relief of moderate to severe pain such as that due to surgery, cancer, trauma/injury, or burns.
PharmacodynamicsHydromorphone is a hydrogenated ketone derivative of morphine that acts as a narcotic analgesic. It has a shorter duration of action than morphine. Hydromorphone is approximately 8 times more potent on a milligram basis than morphine. In addition, hydromorphone is better absorbed orally than is morphine. In clinical settings, Hydromorphone exerts its principal pharmacological effect on the central nervous system and gastrointestinal tract. Its primary actions of therapeutic value are analgesia and sedation. Hydromorphone appears to increase the patient's tolerance for pain and to decrease discomfort, although the presence of the pain itself may still be recognized. In addition to analgesia, alterations in mood, euphoria and dysphoria, and drowsiness commonly occur. Opioids also produce respiratory depression by direct action on brain stem respiratory centers.
Mechanism of actionHydromorphone is a narcotic analgesic; its principal therapeutic effect is relief of pain. Hydromorphone interacts predominantly with the opioid mu-receptors. These mu-binding sites are discretely distributed in the human brain, with high densities in the posterior amygdala, hypothalamus, thalamus, nucleus caudatus, putamen, and certain cortical areas. They are also found on the terminal axons of primary afferents within laminae I and II (substantia gelatinosa) of the spinal cord and in the spinal nucleus of the trigeminal nerve. In clinical settings, Hydromorphone exerts its principal pharmacological effect on the central nervous system and gastrointestinal tract. Hydromorphone also binds with kappa-receptors which are thought to mediate spinal analgesia, miosis and sedation.
Related Articles
AbsorptionBetter absorbed orally than morphine
Volume of distributionNot Available
Protein binding20%
Metabolism

Primarily hepatic. After absorption hydromorphone is metabolized by the liver to the glucuronide conjugate which is then excreted in the urine. Hydromorphone is metabolized to the major metabolites hydromorphone-3-glucuronide, hydromorphone-3-glucoside and dihydroisomorphine-6-glucuronide.

SubstrateEnzymesProduct
Hydromorphone
DihydromorphineDetails
Hydromorphone
DihydroisomorphineDetails
Hydromorphone
NorhydromorphoneDetails
Hydromorphone
Hydromorphone 3-beta-O-glucuronideDetails
Hydromorphone
Not Available
Dihydroisomorphine-6-glucuronideDetails
Hydromorphone
Not Available
Hydromorphone-3-glucosideDetails
Hydromorphone
Not Available
Hydromorphone-3-glucuronideDetails
Hydromorphone
Not Available
Hydromorphone-3-sulphateDetails
Dihydromorphine
Dihydromorphine-3-glucuronideDetails
Route of eliminationOnly a small amount of the hydromorphone dose is excreted unchanged in the urine. Most of the dose is excreted as hydromorphone-3-glucuronide along with minor amounts of 6-hydroxy reduction metabolites.
Half life2.6 hours (oral); 18.6 hours for sustained release Palladone
Clearance
  • 1.96 L/min
ToxicityHydromorphone is a schedule II narcotic which can lead to physical dependence or addiction. High doses lead to respiratory depression, nausea, and vomiting. Overdoses lead to extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, and sometimes bradycardia and hypotension. In severe overdosage, apnea, circulatory collapse, cardiac arrest and death may occur.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Hydromorphone Action PathwayDrug actionSMP00410
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9931
Caco-2 permeable+0.8647
P-glycoprotein substrateSubstrate0.8174
P-glycoprotein inhibitor INon-inhibitor0.8497
P-glycoprotein inhibitor IINon-inhibitor0.9641
Renal organic cation transporterInhibitor0.6374
CYP450 2C9 substrateNon-substrate0.7925
CYP450 2D6 substrateSubstrate0.8618
CYP450 3A4 substrateSubstrate0.7571
CYP450 1A2 substrateNon-inhibitor0.6918
CYP450 2C9 inhibitorNon-inhibitor0.9539
CYP450 2D6 inhibitorNon-inhibitor0.5197
CYP450 2C19 inhibitorNon-inhibitor0.8088
CYP450 3A4 inhibitorNon-inhibitor0.8177
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9413
Ames testNon AMES toxic0.7214
CarcinogenicityNon-carcinogens0.9554
BiodegradationNot ready biodegradable0.9815
Rat acute toxicity2.9191 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8906
hERG inhibition (predictor II)Non-inhibitor0.8992
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Purdue pharma lp
  • Purdue pharmaceutical products lp
  • Akorn inc
  • Barr laboratories inc
  • Hospira inc
  • Watson laboratories inc
  • Roxane laboratories inc
  • Mallinckrodt inc
  • Actavis totowa llc
  • Kv pharmaceutical co
  • Lannett holdings inc
  • Tyco healthcare mallinckrodt
Packagers
Dosage forms
FormRouteStrength
Liquidintramuscular; intravenous; subcutaneous2 mg
Liquidoral1 mg
Liquidoral5 mg/5mL
Powder for solutionintramuscular; intravenous; subcutaneous250 mg
Injection, powder, lyophilized, for solutionintramuscular; intravenous; subcutaneous10 mg/mL
Liquidintramuscular; intravenous; subcutaneous10 mg
Liquidintramuscular; intravenous; subcutaneous50 mg
Capsule (sustained-release)oral4.5 mg
Capsule (sustained-release)oral9.0 mg
Capsule (sustained-release)oral12 mg
Capsule (sustained-release)oral18 mg
Capsule (sustained-release)oral24 mg
Capsule (sustained-release)oral30 mg
Capsule (sustained-release)oral3 mg
Capsule (sustained-release)oral6 mg
Injection, solutionintramuscular; intravenous; subcutaneous.5 mg/mL
Injection, solutionintravenous.1 mg/mL
Injection, solutionintravenous.2 mg/mL
Injection, solutionintravenous.4 mg/mL
Injection, solutionintravenous1 mg/mL
Injection, solutionintravenous10 mg/mL
Injection, solutionintravenous2 mg/mL
Solutionintramuscular; intravenous; subcutaneous10 mg
Solutionintramuscular; intravenous; subcutaneous20 mg
Solutionintramuscular; intravenous; subcutaneous50 mg
Solutionintramuscular; intravenous; subcutaneous100 mg
Injectionintramuscular; intravenous; subcutaneous2 mg/mL
Injectionparenteral10 mg/mL
Injection, solutionintramuscular; intravenous; subcutaneous1 mg/mL
Injection, solutionintramuscular; intravenous; subcutaneous10 mg/mL
Injection, solutionintramuscular; intravenous; subcutaneous2 mg/mL
Injection, solutionintramuscular; intravenous; subcutaneous4 mg/mL
Solutionoral1 mg/mL
Solutionoral5 mg/5mL
Suppositoryrectal3 mg/1
Tabletoral2 mg/1
Tabletoral4 mg/1
Tabletoral8 mg/1
Tablet, film coatedoral2 mg/1
Tablet, film coatedoral4 mg/1
Tablet, film coatedoral8 mg/1
Tablet, extended releaseoral12 mg/1
Tablet, extended releaseoral16 mg/1
Tablet, extended releaseoral32 mg/1
Tablet, extended releaseoral8 mg/1
Solutionintramuscular; intravenous; subcutaneous2 mg
Tablet (extended-release)oral16 mg
Tablet (extended-release)oral32 mg
Tablet (extended-release)oral4 mg
Tablet (extended-release)oral8 mg
Capsule (controlled-delivery)oral12 mg
Capsule (controlled-delivery)oral16 mg
Capsule (controlled-delivery)oral24 mg
Syruporal1 mg
Suppositoryrectal3 mg
Tabletoral1 mg
Tabletoral2 mg
Tabletoral4 mg
Tabletoral8 mg
Prices
Unit descriptionCostUnit
Hydromorphone hcl powder166.25USD g
Dilaudid-hp 250 mg vial114.8USD vial
Dilaudid Sterile Powder 250 mg/vial78.99USD vial
HYDROmorphone HCl 6 3 mg Suppository Box54.92USD box
Hydromorphone Hp 50 50 mg/ml13.78USD ml
Dilaudid-Xp 50 mg/ml11.82USD ml
Hydromorphone 3 mg suppository11.11USD suppository
Dilaudid-Hp-Plus 20 mg/ml5.08USD ml
Hydromorphone Hp 20 20 mg/ml4.72USD ml
Hydromorph Contin 30 mg Controlled-Release Capsule4.21USD capsule
Hydromorph Contin 24 mg Controlled-Release Capsule3.52USD capsule
Dilaudid-Hp 10 mg/ml3.14USD ml
Hydromorphone Hp 10 mg/ml2.92USD ml
Hydromorph Contin 18 mg Controlled-Release Capsule2.75USD capsule
Hydromorphone 10 mg/ml ampul2.58USD ml
Pms-Hydromorphone 3 mg Suppository2.42USD suppository
Dilaudid 4 mg/ml ampul2.2USD ml
Dilaudid 8 mg tablet2.19USD tablet
HYDROmorphone HCl 4 mg/ml Solution 1ml Cartridge2.07USD cartridge
Hydromorph Contin 12 mg Controlled-Release Capsule1.91USD capsule
Dilaudid 2 mg/ml ampul1.81USD ml
Dilaudid 1 mg/ml ampul1.64USD ml
Hydromorphone hcl 8 mg tablet1.4USD tablet
Dilaudid 4 mg tablet1.36USD tablet
Hydromorphone 8 mg tablet1.32USD tablet
Dilaudid 2 mg/ml1.28USD ml
Hydromorphone 2 mg/ml1.19USD ml
Hydromorph Contin 6 mg Controlled-Release Capsule1.1USD capsule
Hydromorphone-ns 0.4 mg/ml1.08USD ml
Hydromorphone-ns 0.3 mg/ ml1.05USD ml
Hydromorphone 2 mg/ml vial1.02USD ml
Hydromorphone-ns 25 mg/25 ml1.01USD ml
Dilaudid 2 mg tablet1.0USD tablet
Hydromorphone-ns 2.5 mg/25 ml0.96USD ml
HYDROmorphone HCl 4 mg tablet0.8USD tablet
HYDROmorphone HCl 2 mg tablet0.77USD tablet
Hydromorph Contin 3 mg Controlled-Release Capsule0.73USD capsule
Hydromorphone 4 mg tablet0.72USD tablet
Dilaudid 8 mg Tablet0.55USD tablet
Hydromorphone-ns 0.2 mg/ml0.49USD ml
Hydromorphone 2 mg tablet0.37USD tablet
Pms-Hydromorphone 8 mg Tablet0.37USD tablet
Dilaudid 4 mg Tablet0.35USD tablet
Dilaudid-5 1 mg/ml liquid0.33USD ml
Hydromorphone-ns 5.5 mg/55 ml0.33USD ml
Dilaudid 2 mg Tablet0.23USD tablet
Pms-Hydromorphone 4 mg Tablet0.23USD tablet
Dilaudid 1 mg Tablet0.16USD tablet
Pms-Hydromorphone 2 mg Tablet0.15USD tablet
Pms-Hydromorphone 1 mg Tablet0.1USD tablet
Dilaudid 1 mg/ml Liquid0.09USD ml
Pms-Hydromorphone 1 mg/ml Liquid0.07USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5968551 No1994-12-242011-12-24Us
US6589960 No2000-11-092020-11-09Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point266.5 °CPhysProp
logP0.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility4.39 mg/mLALOGPS
logP1.69ALOGPS
logP1.62ChemAxon
logS-1.8ALOGPS
pKa (Strongest Acidic)10.11ChemAxon
pKa (Strongest Basic)8.59ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area49.77 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity78.26 m3·mol-1ChemAxon
Polarizability30.02 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-002r-6960000000-9f3d9b17d56e032d76c5View in MoNA
References
Synthesis Reference

Anne M. Hailes, Christopher E. French, Neil C. Bruce, “Morphinone reductase for the preparation of hydromorphone and hydrocodone.” U.S. Patent US5571685, issued November, 1990.

US5571685
General References
  1. Coda BA, Rudy AC, Archer SM, Wermeling DP: Pharmacokinetics and bioavailability of single-dose intranasal hydromorphone hydrochloride in healthy volunteers. Anesth Analg. 2003 Jul;97(1):117-23, table of contents. [PubMed:12818953 ]
  2. Vallner JJ, Stewart JT, Kotzan JA, Kirsten EB, Honigberg IL: Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects. J Clin Pharmacol. 1981 Apr;21(4):152-6. [PubMed:6165742 ]
External Links
ATC CodesN02AG04N02AA03
AHFS Codes
  • 28:08.08
PDB EntriesNot Available
FDA labelDownload (78.9 KB)
MSDSDownload (48.3 KB)
Interactions
Drug Interactions
Drug
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Hydromorphone.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Hydromorphone.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Hydromorphone is combined with 7-Nitroindazole.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe risk or severity of adverse effects can be increased when 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE is combined with Hydromorphone.
AbirateroneThe metabolism of Hydromorphone can be decreased when combined with Abiraterone.
AcepromazineAcepromazine may increase the hypotensive activities of Hydromorphone.
AcepromazineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Aceprometazine.
AcetazolamideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Acetazolamide.
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Hydromorphone.
adipiplonThe risk or severity of adverse effects can be increased when Hydromorphone is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Alfentanil.
AlimemazineAlimemazine may increase the hypotensive activities of Hydromorphone.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Alprazolam.
AlvimopanThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Alvimopan.
AmilorideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Amiloride.
AmiodaroneThe metabolism of Hydromorphone can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Amitriptyline.
Ammonium chlorideAmmonium chloride may increase the excretion rate of Hydromorphone which could result in a higher serum level.
AmobarbitalThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Amobarbital.
AmoxapineHydromorphone may increase the serotonergic activities of Amoxapine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Hydromorphone.
AmperozideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Amperozide.
AmphetamineAmphetamine may increase the analgesic activities of Hydromorphone.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Hydromorphone.
AprepitantThe serum concentration of Hydromorphone can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Aripiprazole.
ArtemetherThe metabolism of Hydromorphone can be decreased when combined with Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Asenapine.
AtazanavirThe metabolism of Hydromorphone can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Hydromorphone can be decreased when combined with Atomoxetine.
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Hydromorphone.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Hydromorphone.
AzaperoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Azaperone.
AzelastineHydromorphone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Hydromorphone.
AzosemideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Azosemide.
BaclofenThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Barbital.
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Hydromorphone.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Bendroflumethiazide.
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Hydromorphone.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Hydromorphone.
BenzocaineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Benzocaine.
BenzphetamineBenzphetamine may increase the analgesic activities of Hydromorphone.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Benzyl alcohol.
BetaxololThe metabolism of Hydromorphone can be decreased when combined with Betaxolol.
BexaroteneThe serum concentration of Hydromorphone can be decreased when it is combined with Bexarotene.
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Hydromorphone.
BoceprevirThe metabolism of Hydromorphone can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Hydromorphone can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Hydromorphone can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.
BrimonidineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Brotizolam.
BumetanideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Bumetanide.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Hydromorphone.
BuprenorphineBuprenorphine may decrease the analgesic activities of Hydromorphone.
BuprenorphineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Buprenorphine.
BupropionThe metabolism of Hydromorphone can be decreased when combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Buspirone.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Hydromorphone.
ButacaineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Butethal.
ButorphanolButorphanol may decrease the analgesic activities of Hydromorphone.
ButorphanolThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Butorphanol.
Canrenoic acidThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Canrenoic acid.
CapecitabineThe metabolism of Hydromorphone can be decreased when combined with Capecitabine.
CarbamazepineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Carbamazepine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Carisoprodol.
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Hydromorphone.
CelecoxibThe metabolism of Hydromorphone can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Hydromorphone can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlordiazepoxide.
ChlormezanoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Chloroprocaine.
ChloroquineThe metabolism of Hydromorphone can be decreased when combined with Chloroquine.
ChlorothiazideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlorphenamine.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Hydromorphone.
ChlorphentermineChlorphentermine may increase the analgesic activities of Hydromorphone.
ChlorpromazineChlorpromazine may increase the hypotensive activities of Hydromorphone.
ChlorpromazineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlorprothixene.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Hydromorphone can be decreased when combined with Cholecalciferol.
CimetidineThe metabolism of Hydromorphone can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Hydromorphone can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Cinchocaine.
CitalopramHydromorphone may increase the serotonergic activities of Citalopram.
CitalopramThe metabolism of Hydromorphone can be decreased when combined with Citalopram.
ClarithromycinThe metabolism of Hydromorphone can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Hydromorphone can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Clidinium.
ClobazamThe metabolism of Hydromorphone can be decreased when combined with Clobazam.
ClobazamThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Hydromorphone is combined with clomethiazole.
ClomipramineHydromorphone may increase the serotonergic activities of Clomipramine.
ClomipramineThe metabolism of Hydromorphone can be decreased when combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Clorazepate.
ClotrimazoleThe metabolism of Hydromorphone can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Hydromorphone can be decreased when combined with Clozapine.
ClozapineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Clozapine.
CobicistatThe serum concentration of Hydromorphone can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Hydromorphone.
ConivaptanThe serum concentration of Hydromorphone can be increased when it is combined with Conivaptan.
ConivaptanThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Conivaptan.
CrizotinibThe metabolism of Hydromorphone can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Cyclobenzaprine.
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Hydromorphone.
CyclosporineThe metabolism of Hydromorphone can be decreased when combined with Cyclosporine.
CyclothiazideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Cyclothiazide.
CyproheptadineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Cyproheptadine.
DabrafenibThe serum concentration of Hydromorphone can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Hydromorphone.
DapoxetineHydromorphone may increase the serotonergic activities of Dapoxetine.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Hydromorphone.
DarunavirThe serum concentration of Hydromorphone can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Hydromorphone can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Hydromorphone can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Hydromorphone can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Desflurane.
DesipramineThe metabolism of Hydromorphone can be decreased when combined with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Hydromorphone.
DesmopressinThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Desmopressin.
DetomidineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Detomidine.
DexamethasoneThe serum concentration of Hydromorphone can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dexbrompheniramine.
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Hydromorphone.
DexmedetomidineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dexmedetomidine.
DextroamphetamineDextroamphetamine may increase the analgesic activities of Hydromorphone.
DextromoramideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Diazepam.
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Hydromorphone.
DifenoxinThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dihydrocodeine.
DihydroergotamineThe metabolism of Hydromorphone can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dihydromorphine.
DiltiazemThe metabolism of Hydromorphone can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dimenhydrinate.
DiphenhydramineThe metabolism of Hydromorphone can be decreased when combined with Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Diphenoxylate.
DoramectinThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Doxepin.
DoxycyclineThe metabolism of Hydromorphone can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.
DoxylamineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Hydromorphone is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.
DronedaroneThe metabolism of Hydromorphone can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Droperidol.
DrospirenoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Drospirenone.
DrotebanolThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Drotebanol.
DuloxetineThe metabolism of Hydromorphone can be decreased when combined with Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dyclonine.
EcgonineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Hydromorphone is combined with ECGONINE METHYL ESTER.
EfavirenzThe serum concentration of Hydromorphone can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Efavirenz.
EfonidipineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Efonidipine.
EliglustatThe metabolism of Hydromorphone can be decreased when combined with Eliglustat.
EluxadolineHydromorphone may increase the constipating activities of Eluxadoline.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Hydromorphone.
EntacaponeThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Entacapone.
EnzalutamideThe serum concentration of Hydromorphone can be decreased when it is combined with Enzalutamide.
EplerenoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Eplerenone.
ErythromycinThe metabolism of Hydromorphone can be decreased when combined with Erythromycin.
EscitalopramHydromorphone may increase the serotonergic activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Hydromorphone can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Eszopiclone.
Etacrynic acidThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Etacrynic acid.
EthanolHydromorphone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Hydromorphone.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Hydromorphone.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Hydromorphone.
EthosuximideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethotoin.
EthoxzolamideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethoxzolamide.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Hydromorphone.
EtoperidoneHydromorphone may increase the serotonergic activities of Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Etorphine.
EtravirineThe serum concentration of Hydromorphone can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Fencamfamine.
FenfluramineHydromorphone may increase the serotonergic activities of Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Fentanyl.
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Hydromorphone.
FexofenadineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Flibanserin.
FloxuridineThe metabolism of Hydromorphone can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Hydromorphone can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Flunitrazepam.
FluorouracilThe metabolism of Hydromorphone can be decreased when combined with Fluorouracil.
FluoxetineHydromorphone may increase the serotonergic activities of Fluoxetine.
FluoxetineThe metabolism of Hydromorphone can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Flupentixol.
FluphenazineFluphenazine may increase the hypotensive activities of Hydromorphone.
FluphenazineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Fluticasone Propionate.
FluvastatinThe metabolism of Hydromorphone can be decreased when combined with Fluvastatin.
FluvoxamineHydromorphone may increase the serotonergic activities of Fluvoxamine.
FluvoxamineThe metabolism of Hydromorphone can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Hydromorphone can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Hydromorphone can be increased when it is combined with Fosaprepitant.
FosphenytoinThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Fospropofol.
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Hydromorphone.
FurosemideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Furosemide.
Fusidic AcidThe serum concentration of Hydromorphone can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Hydromorphone is combined with gabapentin enacarbil.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Hydromorphone.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Gamma Hydroxybutyric Acid.
GemfibrozilThe metabolism of Hydromorphone can be decreased when combined with Gemfibrozil.
GlutethimideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Glutethimide.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Hydromorphone.
GuanfacineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Halazepam.
HaloperidolThe metabolism of Hydromorphone can be decreased when combined with Haloperidol.
HaloperidolThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Heroin.
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Hydromorphone.
HexobarbitalThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Hexobarbital.
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Hydromorphone.
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Hydromorphone.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Hydrocodone.
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Hydroflumethiazide.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may increase the analgesic activities of Hydromorphone.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.
HydroxyzineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Hydroxyzine.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Hydromorphone.
IdelalisibThe serum concentration of Hydromorphone can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Iloperidone.
ImatinibThe metabolism of Hydromorphone can be decreased when combined with Imatinib.
ImipramineThe metabolism of Hydromorphone can be decreased when combined with Imipramine.
ImipramineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Imipramine.
IndalpineHydromorphone may increase the serotonergic activities of Indalpine.
IndapamideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Indapamide.
IndinavirThe metabolism of Hydromorphone can be decreased when combined with Indinavir.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Hydromorphone.
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Hydromorphone.
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Hydromorphone.
IrbesartanThe metabolism of Hydromorphone can be decreased when combined with Irbesartan.
IsavuconazoniumThe metabolism of Hydromorphone can be decreased when combined with Isavuconazonium.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Hydromorphone.
IsofluraneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Isoflurane.
IsoniazidThe metabolism of Hydromorphone can be decreased when combined with Isoniazid.
IsosorbideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Isosorbide.
IsradipineThe metabolism of Hydromorphone can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Hydromorphone can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Hydromorphone can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ketobemidone.
KetoconazoleThe metabolism of Hydromorphone can be decreased when combined with Ketoconazole.
KW-3902The risk or severity of adverse effects can be increased when Hydromorphone is combined with KW-3902.
LamotrigineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Lamotrigine.
LeflunomideThe metabolism of Hydromorphone can be decreased when combined with Leflunomide.
LevetiracetamThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Levomethadyl Acetate.
LevomilnacipranHydromorphone may increase the serotonergic activities of Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Levorphanol.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Hydromorphone.
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Hydromorphone.
LithiumThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Lofentanil.
LopinavirThe metabolism of Hydromorphone can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Hydromorphone.
LorcaserinThe metabolism of Hydromorphone can be decreased when combined with Lorcaserin.
LosartanThe metabolism of Hydromorphone can be decreased when combined with Losartan.
LovastatinThe metabolism of Hydromorphone can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Loxapine.
Lu AA21004Hydromorphone may increase the serotonergic activities of Lu AA21004.
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Hydromorphone.
LuliconazoleThe serum concentration of Hydromorphone can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Hydromorphone can be decreased when it is combined with Lumacaftor.
LumefantrineThe metabolism of Hydromorphone can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Magnesium Sulfate.
MannitolThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Mannitol.
MaprotilineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Maprotiline.
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Hydromorphone.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Hydromorphone.
MeclizineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Melperone.
MephentermineMephentermine may increase the analgesic activities of Hydromorphone.
MepivacaineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Meprobamate.
MersalylThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Mersalyl.
MesoridazineMesoridazine may increase the hypotensive activities of Hydromorphone.
MesoridazineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Metaxalone.
MethadoneThe metabolism of Hydromorphone can be decreased when combined with Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methadyl Acetate.
MethamphetamineMethamphetamine may increase the analgesic activities of Hydromorphone.
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Hydromorphone.
MethapyrileneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methaqualone.
MethazolamideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methazolamide.
MethocarbamolThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methohexital.
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Hydromorphone.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methsuximide.
MethyclothiazideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methyclothiazide.
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Hydromorphone.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methylphenobarbital.
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Hydromorphone.
MetolazoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Metolazone.
MetoprololThe metabolism of Hydromorphone can be decreased when combined with Metoprolol.
MetyrosineHydromorphone may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Midazolam.
MifepristoneThe metabolism of Hydromorphone can be decreased when combined with Mifepristone.
MilnacipranHydromorphone may increase the serotonergic activities of Milnacipran.
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Hydromorphone.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.
MirabegronThe metabolism of Hydromorphone can be decreased when combined with Mirabegron.
MirtazapineHydromorphone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Hydromorphone.
MitotaneThe serum concentration of Hydromorphone can be decreased when it is combined with Mitotane.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Hydromorphone.
ModafinilThe serum concentration of Hydromorphone can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Molindone.
MoricizineMoricizine may increase the hypotensive activities of Hydromorphone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Hydromorphone.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Hydromorphone.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.
NabiloneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Nabilone.
NafcillinThe serum concentration of Hydromorphone can be decreased when it is combined with Nafcillin.
NalbuphineNalbuphine may decrease the analgesic activities of Hydromorphone.
NalbuphineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Nalbuphine.
NaltrexoneThe therapeutic efficacy of Hydromorphone can be decreased when used in combination with Naltrexone.
NefazodoneThe metabolism of Hydromorphone can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Hydromorphone can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Hydromorphone can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Hydromorphone can be decreased when combined with Nevirapine.
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Hydromorphone.
NicardipineThe metabolism of Hydromorphone can be decreased when combined with Nicardipine.
NilotinibThe metabolism of Hydromorphone can be decreased when combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Nortriptyline.
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Hydromorphone.
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Hydromorphone.
OlanzapineHydromorphone may increase the serotonergic activities of Olanzapine.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Hydromorphone.
OlaparibThe metabolism of Hydromorphone can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Olopatadine.
OmeprazoleThe metabolism of Hydromorphone can be decreased when combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Opium.
OrphenadrineHydromorphone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Hydromorphone.
OsanetantThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Osanetant.
OsimertinibThe serum concentration of Hydromorphone can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Oxazepam.
OxprenololThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Oxybuprocaine.
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Hydromorphone.
OxycodoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Oxymorphone.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Hydromorphone.
PalbociclibThe serum concentration of Hydromorphone can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Paliperidone.
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Hydromorphone.
PanobinostatThe metabolism of Hydromorphone can be decreased when combined with Panobinostat.
ParaldehydeHydromorphone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Hydromorphone.
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Hydromorphone.
ParoxetineHydromorphone may increase the serotonergic activities of Paroxetine.
ParoxetineThe metabolism of Hydromorphone can be decreased when combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Hydromorphone can be decreased when it is combined with Peginterferon alfa-2b.
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Hydromorphone.
PentazocinePentazocine may decrease the analgesic activities of Hydromorphone.
PentazocineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Hydromorphone.
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Hydromorphone.
PerampanelThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Perospirone.
PerphenazinePerphenazine may increase the hypotensive activities of Hydromorphone.
PerphenazineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Pethidine.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Hydromorphone.
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Hydromorphone.
PhenobarbitalThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Phenoxyethanol.
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Hydromorphone.
PhenterminePhentermine may increase the analgesic activities of Hydromorphone.
PhenytoinThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Pimozide.
PipamperoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Pipamperone.
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Hydromorphone.
PipotiazineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Pipotiazine.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Hydromorphone.
PiretanideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Piretanide.
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Hydromorphone.
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Hydromorphone.
PizotifenThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Pizotifen.
PolythiazideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Pomalidomide.
PosaconazoleThe metabolism of Hydromorphone can be decreased when combined with Posaconazole.
PotassiumThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Potassium.
Potassium CitrateThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Potassium Citrate.
PramipexoleHydromorphone may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Hydromorphone.
PrilocaineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Prilocaine.
PrimidoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Procaine.
ProchlorperazineProchlorperazine may increase the hypotensive activities of Hydromorphone.
ProchlorperazineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Prochlorperazine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Hydromorphone.
PromazinePromazine may increase the hypotensive activities of Hydromorphone.
PromazineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Promazine.
PromethazinePromethazine may increase the hypotensive activities of Hydromorphone.
PromethazineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Promethazine.
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Hydromorphone.
ProparacaineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Proparacaine.
PropofolThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Hydromorphone is combined with PSD502.
PyrimethamineThe metabolism of Hydromorphone can be decreased when combined with Pyrimethamine.
QuazepamThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Quetiapine.
QuinethazoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Quinethazone.
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Hydromorphone.
QuinineThe metabolism of Hydromorphone can be decreased when combined with Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ramelteon.
RamosetronHydromorphone may increase the constipating activities of Ramosetron.
RanolazineThe metabolism of Hydromorphone can be decreased when combined with Ranolazine.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Hydromorphone.
RemifentanilThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Remifentanil.
RemoxiprideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Hydromorphone.
RifabutinThe metabolism of Hydromorphone can be increased when combined with Rifabutin.
RifampicinThe metabolism of Hydromorphone can be increased when combined with Rifampicin.
RifapentineThe metabolism of Hydromorphone can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Risperidone.
RitonavirThe metabolism of Hydromorphone can be decreased when combined with Ritonavir.
RolapitantThe metabolism of Hydromorphone can be decreased when combined with Rolapitant.
RomifidineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Romifidine.
RopiniroleHydromorphone may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Hydromorphone can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Hydromorphone.
RotigotineHydromorphone may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Hydromorphone.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Hydromorphone is combined with S-Ethylisothiourea.
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Hydromorphone.
SaquinavirThe metabolism of Hydromorphone can be decreased when combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Hydromorphone.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Hydromorphone.
SecobarbitalThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Secobarbital.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Hydromorphone.
SertindoleThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Sertindole.
SertralineHydromorphone may increase the serotonergic activities of Sertraline.
SertralineThe metabolism of Hydromorphone can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Sevoflurane.
SildenafilThe metabolism of Hydromorphone can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Hydromorphone can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Hydromorphone can be increased when it is combined with Simeprevir.
Sodium oxybateThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Sodium oxybate.
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Hydromorphone.
SorafenibThe metabolism of Hydromorphone can be decreased when combined with Sorafenib.
SpironolactoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Spironolactone.
St. John's WortThe serum concentration of Hydromorphone can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Stiripentol.
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Hydromorphone.
SufentanilThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Sufentanil.
SulfadiazineThe metabolism of Hydromorphone can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Hydromorphone can be decreased when combined with Sulfamethoxazole.
SulfisoxazoleThe metabolism of Hydromorphone can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Sulpiride.
SuvorexantThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Tasimelteon.
TelaprevirThe metabolism of Hydromorphone can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Hydromorphone can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Hydromorphone.
TerbinafineThe metabolism of Hydromorphone can be decreased when combined with Terbinafine.
TetrabenazineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Tetrodotoxin.
ThalidomideHydromorphone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Hydromorphone.
TheobromineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Theobromine.
ThiamylalThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Thiamylal.
ThiethylperazineThiethylperazine may increase the hypotensive activities of Hydromorphone.
ThiopentalThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Thiopental.
ThioridazineThioridazine may increase the hypotensive activities of Hydromorphone.
ThioridazineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Tiagabine.
TicagrelorThe metabolism of Hydromorphone can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Hydromorphone can be decreased when combined with Ticlopidine.
TicrynafenThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ticrynafen.
TiletamineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Tiletamine.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Hydromorphone.
TipranavirThe metabolism of Hydromorphone can be decreased when combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Tizanidine.
TocilizumabThe serum concentration of Hydromorphone can be decreased when it is combined with Tocilizumab.
TolbutamideThe metabolism of Hydromorphone can be decreased when combined with Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Tolcapone.
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Hydromorphone.
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Hydromorphone.
TolvaptanThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Tolvaptan.
TopiramateThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Topiramate.
TorasemideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Torasemide.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Hydromorphone.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Hydromorphone.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Hydromorphone.
TrazodoneHydromorphone may increase the serotonergic activities of Trazodone.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Hydromorphone.
TriamtereneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Triamterene.
TriazolamThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Triazolam.
TrichlormethiazideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Trichlormethiazide.
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Hydromorphone.
TrifluoperazineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Trifluoperazine.
TriflupromazineTriflupromazine may increase the hypotensive activities of Hydromorphone.
TriflupromazineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Triflupromazine.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Hydromorphone.
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Hydromorphone.
TrimethoprimThe metabolism of Hydromorphone can be decreased when combined with Trimethoprim.
TrimipramineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Triprolidine.
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Hydromorphone.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Hydromorphone.
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Hydromorphone.
UlaritideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ularitide.
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Hydromorphone.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Hydromorphone.
ValsartanThe metabolism of Hydromorphone can be decreased when combined with Valsartan.
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Hydromorphone.
VenlafaxineThe metabolism of Hydromorphone can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Hydromorphone can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Vigabatrin.
VilazodoneHydromorphone may increase the serotonergic activities of Vilazodone.
VoriconazoleThe metabolism of Hydromorphone can be decreased when combined with Voriconazole.
VortioxetineHydromorphone may increase the serotonergic activities of Vortioxetine.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Hydromorphone.
XylazineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Xylazine.
ZafirlukastThe metabolism of Hydromorphone can be decreased when combined with Zafirlukast.
ZaleplonThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ziconotide.
ZimelidineHydromorphone may increase the serotonergic activities of Zimelidine.
ZiprasidoneThe metabolism of Hydromorphone can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Zolpidem.
ZonisamideThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Zuclopenthixol.
Food Interactions
  • Take without regard to meals. Avoid alcohol.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. Quigley C: Hydromorphone for acute and chronic pain. Cochrane Database Syst Rev. 2002;(1):CD003447. [PubMed:11869661 ]
  2. Inturrisi CE: Clinical pharmacology of opioids for pain. Clin J Pain. 2002 Jul-Aug;18(4 Suppl):S3-13. [PubMed:12479250 ]
  3. Sarhill N, Walsh D, Nelson KA: Hydromorphone: pharmacology and clinical applications in cancer patients. Support Care Cancer. 2001 Mar;9(2):84-96. [PubMed:11305075 ]
  4. Kumar P, Sunkaraneni S, Sirohi S, Dighe SV, Walker EA, Yoburn BC: Hydromorphone efficacy and treatment protocol impact on tolerance and mu-opioid receptor regulation. Eur J Pharmacol. 2008 Nov 12;597(1-3):39-45. doi: 10.1016/j.ejphar.2008.08.025. Epub 2008 Aug 30. [PubMed:18789923 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
partial agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurot...
Gene Name:
OPRD1
Uniprot ID:
P41143
Molecular Weight:
40368.235 Da
References
  1. Fang X, Larson DL, Portoghese PS: 7-spirobenzocyclohexyl derivatives of naltrexone, oxymorphone, and hydromorphone as selective opioid receptor ligands. J Med Chem. 1997 Sep 12;40(19):3064-70. [PubMed:9301669 ]
  2. Hennies HH, Friderichs E, Schneider J: Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids. Arzneimittelforschung. 1988 Jul;38(7):877-80. [PubMed:2849950 ]
  3. Jiang Q, Sebastian A, Archer S, Bidlack JM: 5 beta-Methyl-14 beta-(p-nitrocinnamoylamino)-7,8-dihydromorphinone and its corresponding N-cyclopropylmethyl analog, N-cyclopropylmethylnor-5 beta-methyl-14 beta-(p-nitrocinnamoylamino)- 7,8-dihydromorphinone: mu-selective irreversible opioid antagonists. J Pharmacol Exp Ther. 1994 Mar;268(3):1107-13. [PubMed:7511163 ]
  4. Guay DR: Use of oral oxymorphone in the elderly. Consult Pharm. 2007 May;22(5):417-30. [PubMed:17658959 ]
  5. Hartvig P, Neil A, Terenius L, Antoni G, Rimland A, Ulin J, Langstrom B: Brain and plasma kinetics of the opioid 11C-hydromorphone in two macaque species. Pharmacol Toxicol. 1989 Sep;65(3):214-6. [PubMed:2478994 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates th...
Gene Name:
OPRK1
Uniprot ID:
P41145
Molecular Weight:
42644.665 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Gharagozlou P, Hashemi E, DeLorey TM, Clark JD, Lameh J: Pharmacological profiles of opioid ligands at kappa opioid receptors. BMC Pharmacol. 2006 Jan 25;6:3. [PubMed:16433932 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A9
Uniprot ID:
O60656
Molecular Weight:
59940.495 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 31, 2016 02:12